Everest Medicines
Everest Medicines, a biopharmaceutical company, discovers, develops, manufactures and commercializes medicines for patients with critical unmet medical needs globally.
- Public company
- Shanghai, CNChina
Everest Medicines, a biopharmaceutical company, discovers, develops, manufactures and commercializes medicines for patients with critical unmet medical needs globally.
everestmedicines.comCrawled Oct 25, 2026
Everest Medicines reports interim financial and operational results for the first half of 2026. The company highlights progress in its pipeline, including clinical advancements for key drug candidates. Revenue growth and strategic partnerships are noted as key drivers in the update.
Aug 2026Macau BusinessNews article
Everest Medicines secures exclusive rights to develop and commercialize **civorebrutinib (EVER001)**, an oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, through a licensing deal with **Travere Therapeutics**. The agreement grants Everest global development and commercialization control for the potential best-in-class therapy. Civorebrutinib targets autoimmune and inflammatory diseases, leveraging Travere’s preclinical and clinical data.
Jul 2026Yahoo FinanceNews article
Everest Medicines partners with Hasten to commercialize six mature drug assets targeting critical care, cardiovascular, and metabolic diseases. The agreement leverages Everest’s established services to support Hasten’s portfolio expansion. Both companies collaborate under a license agreement to accelerate market access for these therapies.
Dec 2025PR NewswireNews article
Everest Medicines secures an agreement with Gilead Sciences to distribute **Trodelvy**, a chemotherapy drug, across Asia territories. The collaboration expands Everest’s commercial reach in oncology treatments, leveraging Gilead’s established portfolio. The deal aligns with Everest’s focus on developing and commercializing biopharmaceuticals in emerging markets.
Aug 2022PR NewswireNews article